BioScrip (BIOS) Tops Q3 Views
BIOS Hot Sheet
Revenue Growth %: -64.6%Financial Fact:
Restructuring expense: 300K
Today's EPS Names:
TARO, BRLI, TLB, More
BioScrip, Inc. (Nasdaq: BIOS) reports Q3 EPS of $0.06, ex-items, 1 cent better than the analyst estimate of $0.05. Revenue for the quarter was $359.4 million, versus the consensus of $356.99 million.
BioScrip, Inc., a specialty pharmaceutical healthcare organization, provides medications and management solutions for chronic and other healthcare conditions in the United States.
BioScrip, Inc., a specialty pharmaceutical healthcare organization, provides medications and management solutions for chronic and other healthcare conditions in the United States.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
- Taro Pharmaceutical Industries (TARO) Nearly Doubles Q1 EPS to 1.06
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
